TY - JOUR
T1 - Combination lithium and divalproex sodium in pediatric bipolarity
AU - Findling, Robert L.
AU - McNamara, Nora K.
AU - Gracious, Barbara L.
AU - Youngstrom, Eric A.
AU - Stansbrey, Robert J.
AU - Reed, Michael D.
AU - Demeter, Christine A.
AU - Branicky, Lisa A.
AU - Fisher, Kathryn E.
AU - Calabrese, Joseph R.
N1 - Funding Information:
Supported by a Clinical Research Center Grant from the Stanley Medical Research Institute, a Pediatric Pharmacology Research Unit grant (HD 31323-02) , and the Children's Research Foundation of Cleveland. Study medication was supplied in part by Abbott Laboratories.
PY - 2003/8
Y1 - 2003/8
N2 - Objective: Lithium carbonate (Li) or divalproex sodium (DVPX) may be effective for some juveniles with bipolar disorder. Many youths with bipolar disorder do not respond to DVPX or Li monotherapy. An open-label study was conducted to examine the effectiveness of combination DVPX and Li therapy with youths diagnosed with bipolar disorder. Method: Patients meeting DSM-IV criteria for bipolar I or bipolar II disorder, ages 5 to 17 years, were treated prospectively for up to 20 weeks with DVPX + Li. Assessments included the Young Mania Rating Scale (YMRS), Children's Depression Rating Scale-Revised (CDRS-R), and the Children's Global Assessment Scale (CGAS). The a priori definition of clinical remission utilized included four contiguous weekly ratings of YMRS ≤12.5, CDRS-R ≤40, CGAS ≥51, clinical stability, and no evidence of mood cycling. Results: Ninety patients (66 males, 24 females) were treated. Significant improvement (p < .0001) in all outcome measures was observed by week 8 as well as at the end of study. The mean time in study was 11.3 weeks. Forty-seven percent (n = 42) met a priori criteria for remission. Conclusions: Symptoms of mania and depression in juvenile bipolar disorder may be safely and effectively treated acutely with DVPX + Li.
AB - Objective: Lithium carbonate (Li) or divalproex sodium (DVPX) may be effective for some juveniles with bipolar disorder. Many youths with bipolar disorder do not respond to DVPX or Li monotherapy. An open-label study was conducted to examine the effectiveness of combination DVPX and Li therapy with youths diagnosed with bipolar disorder. Method: Patients meeting DSM-IV criteria for bipolar I or bipolar II disorder, ages 5 to 17 years, were treated prospectively for up to 20 weeks with DVPX + Li. Assessments included the Young Mania Rating Scale (YMRS), Children's Depression Rating Scale-Revised (CDRS-R), and the Children's Global Assessment Scale (CGAS). The a priori definition of clinical remission utilized included four contiguous weekly ratings of YMRS ≤12.5, CDRS-R ≤40, CGAS ≥51, clinical stability, and no evidence of mood cycling. Results: Ninety patients (66 males, 24 females) were treated. Significant improvement (p < .0001) in all outcome measures was observed by week 8 as well as at the end of study. The mean time in study was 11.3 weeks. Forty-seven percent (n = 42) met a priori criteria for remission. Conclusions: Symptoms of mania and depression in juvenile bipolar disorder may be safely and effectively treated acutely with DVPX + Li.
KW - Bipolar disorder
KW - Divalproex
KW - Lithium
UR - http://www.scopus.com/inward/record.url?scp=0042831250&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0042831250&partnerID=8YFLogxK
U2 - 10.1097/01.CHI.0000046893.27264.53
DO - 10.1097/01.CHI.0000046893.27264.53
M3 - Article
C2 - 12874490
AN - SCOPUS:0042831250
SN - 0890-8567
VL - 42
SP - 895
EP - 901
JO - Journal of the American Academy of Child and Adolescent Psychiatry
JF - Journal of the American Academy of Child and Adolescent Psychiatry
IS - 8
ER -